TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
GYRE

Gyre Therapeutics Inc.

Healthcare · Biotechnology

7.40$ +0.3% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns Gyre Therapeutics Inc. (GYRE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 33.9% of the shares are freely tradable; institutional investors hold 3.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 3.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 74.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 33.9%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 106Mio.

Largest Shareholders

Institutions

Institutions GYRE
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 0.93 984,204 +0.0 03/31/2026
Octagon Capital Advisors LP 0.90 954,416 +0.0 06/30/2026
BlackRock Inc 0.72 758,630 +5.3 03/31/2026
Geode Capital Management, LLC 0.41 431,414 +1.9 03/31/2026
State Street Corp 0.20 216,326 +7.0 03/31/2026
SBI Securities Co Ltd 0.16 170,837 +4.9 03/31/2026
Charles Schwab Investment Management Inc 0.16 165,238 -2.3 03/31/2026

Funds

Funds GYRE
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 0.58 614,654 +0.0 08/31/2026
iShares Russell 2000 ETF 0.37 388,437 -0.6 08/31/2026
Fidelity Small Cap Index 0.19 200,152 +73.1 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?